A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)
Latest Information Update: 27 Feb 2026
At a glance
- Drugs Trospium chloride/xanomeline (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 05 Feb 2026 Status changed from not yet recruiting to recruiting.
- 24 Dec 2025 New trial record